Chesapeake Urology Associates

Page Options

Bladder Cancer

If you have been diagnosed with recurrent high grade bladder cancer, you may qualify for this research study.

#1: Open label, multi-center study of the efficacy and safety of MCC in the treatment of patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG

For additional information go to: www.bioniche.com

Research Location:
Towson, MD
8322 Bellona Ave., Suite 202
Towson, MD 21204
Contact Debi Robertson, drobertson@cua.md or 410-825-6310 x163

#2: A multicenter, randomized, placebo-controlled, double-blind, Phase 3 trial of single-dose Intravesical Eoquin(R) as a surgical adjuvant instilled in the early postoperative period in patients undergoing transurethral resection for non-invasive bladder cancer.

For additional information go to: www.spectrumpharm.com

Research Locations:
Towson, MD
8322 Bellona Ave., Suite 202
Towson, MD 21204
Contact Debi Robertson, drobertson@cua.md or 410-825-6310 x163

Franklin Square
6830 Hospital Dr., Suite 204
Baltimore, MD 21237
Contact Angela Somers, asomers@cua.md or 410-391-6131 x1212

« Current Clinical Trials

Erectile Dysfunction (ED)

Enlarged Prostate: (Benign Prostatic Hyperplasia/BPH)

Bladder Cancer

Prostate Cancer

Overactive Bladder